This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gerresheimer Begins Financial Year 2013 With Strong Revenue Growth

DÜSSELDORF, Germany, April 10, 2013 /PRNewswire/ --
  • First-quarter revenues up 10.4% to EUR 296.7m
  • Adjusted EBITDA margin reaches 15.5%
  • Net income grows by 41.7% to EUR  10.2m
  • Adjusted earnings per share increased to EUR 0.36
  • Acquisition in India boosts activities in emerging markets

Gerresheimer AG, one of the leading global partners to the pharma and healthcare industry, increased revenues by 10.4% in the first quarter of the new, 2013 financial year.  "The strong revenue growth in the first quarter largely relates to increased revenues in the Plastic Systems Division. The increase is mostly attributable to higher revenues from engineering services and tools paving the way for future business with drug delivery devices. Our latest acquisitions in India also contributed to the surge in revenues. There is furthermore healthy demand for pharma products overall," said Uwe Röhrhoff, CEO of Gerresheimer AG.

Gerresheimer increased revenues in the first quarter of financial year 2013 ( December 1, 2012 to November 30, 2013) by a substantial 10.4% to EUR 294.7m. The revenue increase was due primarily to strong organic growth in the Plastic Systems Division. This notably generated large revenues with tools and engineering services. There was also favorable demand for drug delivery devices such as insulin pens, asthma inhalers and prefillable glass syringes. Sound revenues were also attributable to primary pharma packaging such as glass injection vials, cartridges as well as plastic containers for solid and liquid medications. The two Indian companies acquired in 2012 - Triveni, a producer of plastic primary pharmaceutical packaging, and Neutral Glass, which produces glass pharmaceutical vials - also contributed to the marked revenue increase compared with the prior year.

The Gerresheimer Group generated adjusted EBITDA of EUR 46.0m in the first quarter of 2013, an increase of 2.1% on the prior-year quarter. The adjusted EBITDA margin was 15.5%, below the 16.8% margin in the comparative period. The main reason for the lower margin was the exceptionally strong revenue growth in engineering services and tools business in the Plastic Systems Division. While the tools business and engineering services have narrower margins, they are important in paving the way for the subsequent production of drug delivery devices. Net income after tax increased relative to the prior-year quarter by 41.7% to EUR 10.2m. Adjusted earnings per share rose by EUR 0.03 to EUR 0.36.

Gerresheimer's capital expenditure in the first quarter of 2013 was EUR 16.6m, EUR 1.7m more than a year earlier. In December 2012, Gerresheimer also purchased 75% of shares in Triveni, the leading Indian producer of pharmaceutical plastic packaging and closures.


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs